Botox And Beyond: Allergan Lays Out Growth Strategy
With Botox now its biggest product, Allergan highlights moves to further the versatile drug’s expansion into new medical indications, as well as efforts to bolster the company’s traditional ophthalmic core, including advancing a pipeline candidate in the increasingly competitive wet-AMD field.
You may also be interested in...
Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.
“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.
As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.